Eyepoint Pharmaceuticals Stock Current Valuation
| EYPT Stock | USD 8.25 0.21 2.48% |
Valuation analysis of Eyepoint Pharmaceuticals helps investors to measure Eyepoint Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to drop to -9.13 in 2024. Enterprise Value Multiple is likely to drop to -9.13 in 2024. Fundamental drivers impacting Eyepoint Pharmaceuticals' valuation include:
Price Book 2.7614 | Enterprise Value 372.2 M | Enterprise Value Ebitda (11.49) | Price Sales 13.2134 | Enterprise Value Revenue 8.141 |
Undervalued
Today
Please note that Eyepoint Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of Eyepoint Pharmaceuticals is based on 3 months time horizon. Increasing Eyepoint Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Eyepoint Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 8.25, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.25 | Real 14.05 | Target 31.75 | Hype 8.37 | Naive 9.48 |
The intrinsic value of Eyepoint Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Eyepoint Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Eyepoint Pharmaceuticals helps investors to forecast how Eyepoint stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Eyepoint Pharmaceuticals more accurately as focusing exclusively on Eyepoint Pharmaceuticals' fundamentals will not take into account other important factors: Eyepoint Pharmaceuticals Company Current Valuation Analysis
Eyepoint Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Eyepoint Pharmaceuticals Current Valuation | 372.15 M |
Most of Eyepoint Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eyepoint Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Eyepoint Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Eyepoint Pharmaceuticals is extremely important. It helps to project a fair market value of Eyepoint Stock properly, considering its historical fundamentals such as Current Valuation. Since Eyepoint Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Eyepoint Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Eyepoint Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Eyepoint Current Valuation Historical Pattern
Today, most investors in Eyepoint Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Eyepoint Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Eyepoint Pharmaceuticals current valuation as a starting point in their analysis.
Eyepoint Pharmaceuticals Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Eyepoint Pharmaceuticals has a Current Valuation of 372.15 M. This is 97.41% lower than that of the Pharmaceuticals sector and 91.99% lower than that of the Health Care industry. The current valuation for all United States stocks is 97.76% higher than that of the company.
Eyepoint Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eyepoint Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eyepoint Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eyepoint Pharmaceuticals by comparing valuation metrics of similar companies.Eyepoint Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Eyepoint Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Eyepoint Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Eyepoint Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Eyepoint Fundamentals
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.31 | ||||
| Profit Margin | (2.27) % | ||||
| Operating Margin | (3.11) % | ||||
| Current Valuation | 372.15 M | ||||
| Shares Outstanding | 68.25 M | ||||
| Shares Owned By Insiders | 1.14 % | ||||
| Shares Owned By Institutions | 93.48 % | ||||
| Number Of Shares Shorted | 9.88 M | ||||
| Price To Earning | (2.82) X | ||||
| Price To Book | 2.76 X | ||||
| Price To Sales | 13.21 X | ||||
| Revenue | 46.02 M | ||||
| Gross Profit | 26.95 M | ||||
| EBITDA | (69 M) | ||||
| Net Income | (70.8 M) | ||||
| Cash And Equivalents | 171.17 M | ||||
| Cash Per Share | 5.02 X | ||||
| Total Debt | 4.91 M | ||||
| Debt To Equity | 0.30 % | ||||
| Current Ratio | 6.16 X | ||||
| Book Value Per Share | 4.09 X | ||||
| Cash Flow From Operations | 1.88 M | ||||
| Short Ratio | 8.42 X | ||||
| Earnings Per Share | (1.99) X | ||||
| Target Price | 33.45 | ||||
| Number Of Employees | 121 | ||||
| Beta | 1.52 | ||||
| Market Capitalization | 604.02 M | ||||
| Total Asset | 355.18 M | ||||
| Retained Earnings | (742.15 M) | ||||
| Working Capital | 281.54 M | ||||
| Current Asset | 15.08 M | ||||
| Current Liabilities | 11.26 M | ||||
| Net Asset | 355.18 M |
About Eyepoint Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eyepoint Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eyepoint Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eyepoint Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Eyepoint Stock Analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.